We are Napo Therapeutics: a European pharmaceutical company, a young start-up led by a team of experienced professionals. Our mission is to improve the quality of life of people suffering from rare diseases and pathologies with a strong unmet medical need through innovative solutions. Our name reflects our story: The Napo River crosses the territories of the Amazon where the Croton lechleri tree grows – the plant from which we extract the sap that contains a unique active ingredient. We are studying an innovative and first-in-class drug thanks to the novel mechanism of action of this active ingredient, in order to register it throughout Europe. Right now, our focus is on two serious rare diseases: short bowel syndrome (SBS) and congenital diarrheal disorders (CDD). Our majority shareholder is Napo Pharmaceuticals, a wholly owned subsidiary of Jaguar Health, which is headquartered in San Francisco, California and listed on NASDAQ (JAGX).
Cincinnati Children's ranks among the top five in the nation in U.S. News & World Report's 2021-22 listing of Best Children's Hospitals. A nonprofit, academic medical center established in 1883, Cincinnati Children's is one of the top three recipients of pediatric research grants from the National Institutes of Health. The medical center is internationally recognized for improving child health and transforming delivery of care through fully integrated, globally recognized research, education, and innovation. Additional information about technologies developed at Cincinnati Children's may be found at Innovation.CincinnatiChildrens.org
Laboratoires CTRS is a French company founded in 2002 to develop, register and market innovative therapies targeted at orphan diseases. Within its portfolio, the company commercialises a therapy for two ultra-rare bile acid synthesis defects. CTRS is fully committed to bring new treatments and satisfy unmet medical needs for extremely small patient population with a special focus on liver disorders. It partners with the healthcare community aiming to improve patients' standard of care. CTRS has been awarded the prestigious 2014 Prix Galien France and 2016 Prix Galien International for its product Orphacol® (cholic acid). MECAPHARMA is the regional representative of Laboratoires CTRS in MENA and through its regional presence and multinational network of collaborators, MECAPHARMA serves the unmet medical needs of rare disease patients in MENA, providing them with lifesaving FDA and EMA approved products.
At Sandoz our work is focused on improving access to medicines, access to medical information and access to medical capacity building. At Sandoz, our purpose is to pioneer access for patients. Our business ambition is to be the world’s leading and most valued generics company. Our global portfolio comprises approximately 1 000 molecules, covering all a wide range of major therapeutic areas, which accounted for 2022 sales of USD 9.2 billion. Our broad offering translates into substantial and ongoing savings for patients and payors, which help to ensure the sustainability of healthcare systems in the face of significant budgetary pressures, while also freeing up funding for innovative medicines. Our products reach approximately 500 million patients every year. Our broad portfolio is spearheaded by our global leadership positions in both biosimilars, the “cutting edge” of innovative off-patent medicines, and generic antibiotics, the backbone of global healthcare systems.
The Kabrita brand is a division of the Ausnutria group. Ausnutria produces and markets formulas for bottle feeds, based on goat milk and organic cow milk, under the brand names Kabrita and Neolac. As well as formula, our brand Kabrita also offers other goat milk-based products for growing infants such as cereal mixes and snacks. We also serve the B2B market by producing private label baby formula, as well as producing and marketing a range of dairy ingredients. Our customers can rely on expertise that has been built on more than 100 years of experience in the dairy industry and top quality supplied from our own production locations in Ommen, Kampen, Leeuwarden and Heerenveen.
We put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. Our partners collaborate with us because of our reputation for quality, our strong brand recognition, and our US FDA-inspected manufacturing plants. Organisations we work with know they can rely on us to deliver consistently, in all our markets. We have always been committed to high standards of ethical conduct. In our business and in our dealings with other people. At the heart of this are our three values: Innovation. Caring. Collaboration. These shape the way our people think, work and behave. And ensure the sustainability of our company. In 2017, we achieved the highest ranking of any pharmaceutical company in the UK’s Institute of Directors' Good Governance Report.
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our teams across the world strive to transform the practice of medicine, turning the impossible into the possible for patients. We provide potentially life-changing treatments and the protection of life-saving vaccines to millions of people, and affordable access to our medicines in some of the world’s poorest countries.
Alphamed was set up in 1982 by Dr. Saad F. Al Khayyat the company that was the foundation of Al Khayyat Investments. Al Khayyat Investments is on the threshold of a dynamic new phase of expansion, both domestically and regionally. Our financial position is strong. We have a committed, mature management team who have built on their rich, cumulative experience, gained across numerous geographies, to lead AKI into a position of strength in the UAE and beyond. Our infrastructure is powerful and well developed. Our vision is to retain our leading position in the market and grow further. Al Khayyat Investments trades across eight operating divisions, led by distinguished professionals drawn from a broad spectrum of industries AVANOS Medical is a medical technology company focused on delivering clinically superior medical device solutions that will help patients get back to the things that matter. AVANOS Medical's products are designed to improve patient outcomes and enhance the efficiency of healthcare delivery. The company focuses on three core areas: pain management, airway management, and digestive health. AVANOS Medical's products for digestive health are designed to improve patient comfort and reduce the risk of complications associated with enteral feeding. The company works closely with healthcare providers to ensure that its products meet the needs of patients with different digestive health conditions.
Genpharm provides fast-track market access to Rare Disease and specialty pharmaceutical companies looking to expand into the Middle East and North Africa (MENA region and Turkey. It is the regional leader in Rare Diseases and the only regional company to have Gene Therapy expertise. Incorporated since 2012, a nancially sound and privately owned company, Genpharm is based in the Dubai Science Park (DSP), U.A.E. It also has an oce in Boston in the heart of the Biotech hub and in Ireland. Operating through evidence-based medicine and the highest ethical standards, Genpharm provides its partners with fast and sustainable market access solutions into the MENA region. Genpharm employs highly qualied and experienced MSLs and KAMs. It oers regulatory, medical, PV and logistical support. Armed with knowledge of the local business culture and the vast network of trusted partners, Genpharm's expertise allows it to create market opportunities for innovative healthcare products and services.
Tebabah Home Health Care- Sole Proprietorship abbreviated as THHC was established since 21 September 2016 located in Quad Al Touba District Al Ain UAE. Tebabah Home Health Care, proffers Home Care Services throughout Abu Dhabi region. With their main services such as Nursing, Physiotherapy/ Occupational and Speech Therapy. Providing the best quality services adhere to the Department of Health and International Health Care Standards.
Ferring is a research-driven, specialty biopharmaceutical group committed to helping people build healthy families and live better lives. Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology.
Biologix helps multinational pharmaceutical manufacturers bring innovative drugs to market in the Middle East / North Africa (MENA) region. Positioned across 17+ key strategic locations in the Gulf Cooperation Council (GCC), Egypt, North Africa and the Levant, we are pioneers in regional distribution and promotion of innovative products and solutions for dicult-to-treat diseases. A privately owned pharmaceutical company organized under the laws of the United Arab Emirates (UAE), Biologix provides end-to-end solutions from the preregistration phase all the way to commercial-scale market access and risk management. Incorporated in the Dubai Airport Free Zone in September 2002, Biologix traces its history back to 1997. We were among the rst organizations to recognize the need for long-term strategic partnerships in the MENA region, and today we connect pharma leaders around the world with integrated direct-access healthcare approaches.
NewBridge Pharmaceuticals, headquartered in Dubai, UAE, is a regional specialty company with a comprehensive pharmaceutical platform of services and expertise, established to bridge the access gap and partner with global pharma and biotech companies to in-license and commercialize U.S. FDA or EMA approved innovative therapeutics that address unmet medical needs into the Middle East and North Africa (MENA) regions.